Thyrocare Q1 FY27: Strong growth, expanding reach, and a measured entry into specialty diagnostics

Thyrocare Technologies Limited began FY27 with a strong quarter, pairing sharp growth with higher profitability. In Q1 FY27, consolidated revenue rose to INR 240.0 crore, up 24.3% year on year. EBITDA increased faster, up 33.8% to INR 77.3 crore, while profit after tax rose 34.1% to INR 51.3 crore. The quarter also showed margin improvement, with consolidated EBITDA margin at 32.2% and PAT margin at 21.4%.

The investor presentation and management commentary framed this performance as the outcome of a five-year effort to rebuild reach and reliability after a period of weaker growth prior to the acquisition by API Holdings in 2021. Management highlighted the scale-up in network, test menu, and clinical infrastructure, while also positioning the next phase of growth as a shift from routine preventive testing into higher complexity specialty diagnostics.

Pathology continued to drive the quarter

The consolidated business remained heavily weighted toward pathology. In Q1 FY27, consolidated pathology revenue was INR 226.5 crore, compared with INR 13.5 crore from radiology. On the standalone pathology view, the revenue split continued to reflect Thyrocare’s B2B-first positioning.

Standalone pathology in Q1 FY27 delivered INR 225.6 crore of revenue, up 26.1% year on year. Within that, franchise revenue was INR 142.8 crore, partnerships contributed INR 71.0 crore, and D2C revenue was INR 11.8 crore. The presentation also summarized this as a 64% franchise, 31% partnerships, and 5% D2C contribution within pathology.

Operational metrics supported the growth narrative. Q1 FY27 patients increased to 5.4 million, up 17% year on year, and tests conducted rose to 55.2 million, up 28% year on year. Quarterly active franchisees increased to 11,730, up 23% year on year.

The company also disclosed that it revised the definition of tests conducted from Q1 FY27 onward to exclude calculated parameters that are not billed to patients, and it provided restated historical test volumes for prior quarters. This improves the linkage between test volume and billed activity, but also means investors should compare test KPIs using the revised series.

Margin expansion supported by execution and scale

Profitability improved faster than revenue. Consolidated gross margin rose to 74.1% in Q1 FY27 from 71.2% in Q1 FY26. Management attributed this to a mix of better negotiations, improved operational efficiency, and volume growth.

Costs also rose, but the company presented them as intentional investments. Employee benefit expense increased due to annual increments, lab expansion, and the build-out of specialty diagnostics capabilities. Management also clarified the continuing ESOP charge, indicating it was about INR 3.5 crore in the quarter.

In standalone results, EBITDA margin was 33.5% and PAT margin was 22.2%, both higher year on year. Management also cited longer-term profitability progress excluding the COVID years, including an EBITDA margin expansion from 23% in FY23 to 32% in FY26 and an increase in ROCE from 15% in FY23 to 34% in FY26.

Network expansion and partner engagement remained central

Thyrocare continued to invest in scale and proximity. The company highlighted a lab network of 44 labs including one international lab in Tanzania. In Q1 FY27, it launched a new Regional Processing Lab in Muzaffarpur and hybrid labs in Prayagraj and Kurnool. Management described the expansion as a way to strengthen turnaround times in nearby catchments and reduce sample travel, with a stated goal that samples should not need to travel to Mumbai except for specialized tests.

The company also emphasized channel partner engagement. It conducted franchisee meetings across multiple locations, including structured partner meets in India and Malaysia. It also conducted 23 doctor meetings with participation from about 100 doctors to strengthen clinical engagement and trust.

Service-level metrics presented in the deck included about 99% on-time phlebo arrival, turnaround time of 3.37 hours, and complaints per million tests at 3.1, which the company said declined 24% year on year. These metrics supported the company’s positioning of diagnostics as a trust-led service, where operational reliability is as important as test pricing.

Specialty diagnostics: early stage, but clear intent

The strategic highlight of the quarter was the commercial go-live of specialty diagnostics, starting with genomics and allergy testing. The presentation listed new additions such as gut microbiome and whole exome sequencing. Management also referenced Phadia-based allergy testing and genomics offerings including NIPT.

Management did not provide near-term revenue guidance for specialty diagnostics, stating it is too early and that the segment remains very small relative to the base. However, it shared a directional ambition: over a three to five year horizon, specialty could become 15% to 20% of the portfolio, in line with peer benchmarks.

A key point in the concall was that the entry is not positioned as a premium pricing move. Management reiterated that affordability remains the core principle, and cited NIPT pricing at less than half of existing market rates as an example. The company expects specialty margins to be broadly in line with current EBITDA margins, provided scale is achieved.

On investment needs, management indicated most capex for specialty has already been made, largely concentrated in central labs in Mumbai and Delhi. Unlike routine testing, specialty can be handled through a more centralized model, limiting the need to deploy expensive equipment across every lab.

Radiology: profitability improved, strategic exits continued

Radiology remained a small part of the consolidated mix, but it was an active area of portfolio decision-making. Q1 FY27 radiology revenue was INR 13.48 crore, down 4% year on year, reflecting a strategic exit from non-profitable centers. Despite the revenue decline, EBITDA rose 23% year on year to INR 2.65 crore, and PAT increased sharply to INR 1.72 crore, helped by lower depreciation following closures.

Management also discussed a possible divestment of the imaging business, noting that the nuclear segment has not been growing and that the company has been conservative on investment given lower return on capital compared with pathology. No timeline was provided.

Key takeaways

Thyrocare’s Q1 FY27 performance reinforced a consistent message: scale and service quality are translating into profitable growth. With pathology still delivering most of the growth engine, the company is extending its playbook into specialty diagnostics through a doctor-led, centralized model while keeping affordability as the guiding principle.

The key questions for the next few quarters are whether franchise and partnership momentum sustains on a higher base, how quickly specialty diagnostics can move beyond a pilot scale, and how decisively the company reshapes the radiology portfolio. For now, Q1 FY27 showed that the core business is expanding with improving margins, and the strategic roadmap is becoming clearer.